Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Retin Cases Brief Rep. 2016 Fall;10(4):357–360. doi: 10.1097/ICB.0000000000000262

Figure 3.

Figure 3

Patient 3 showing response of subretinal disease to intravitreal melphalan. A. Persistent subretinal disease following systemic chemotherapy and 3 infusions of OAC. B. Nine months following 2 intravitreal injections of melphalan, the eye remains tumor free. C & D. One week following the second intravitreal melphalan injection, four quadrants of intraretinal hemorrhage with edema and vasculitis were observed. E. Fluorescein angiogram at that time demonstrates blockage from the hemorrhage, and leaky retinal and choroidal blood vessels. F. The fluorescein angiogram 3 months later demonstrates patchy hypoperfusion of the choroid and retina, particularly superiorly, where the injection was given.